Novartis (NOVN) Given a CHF 95 Price Target by Jefferies Financial Group Analysts

Jefferies Financial Group set a CHF 95 target price on Novartis (VTX:NOVN) in a research note published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. set a CHF 85 price objective on shares of Novartis and gave the stock a sell rating in a report on Wednesday, April 3rd. Credit Suisse Group set a CHF 84 price objective on shares of Novartis and gave the stock a neutral rating in a report on Thursday, April 25th. Deutsche Bank set a CHF 85 price objective on shares of Novartis and gave the stock a neutral rating in a report on Thursday, April 25th. HSBC set a CHF 83 price objective on shares of Novartis and gave the stock a neutral rating in a report on Thursday, April 25th. Finally, Goldman Sachs Group set a CHF 98 price objective on shares of Novartis and gave the stock a buy rating in a report on Wednesday, April 24th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of CHF 88.35.

Novartis has a fifty-two week low of CHF 72.45 and a fifty-two week high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Story: What kind of dividend yield to CEF’s pay?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.